Announcement: Multiple Sclerosis Conference

Cambridge Healthtech Institute inquiries at healthtech.com
Wed Nov 22 15:36:48 EST 1995


Cambridge Healthtech Institute, producer of meetings of interest to
biomedical professionals, is announcing their upcoming meeting,
"Prevention and Treatment of Multiple Sclerosis:The New Autoimmunity
Model" to be held: April 1-2, 1996 in Atlanta, Georgia.

Conference Overview:
Development of an Infrastructure Suitable for Highthroughput
Genotyping:  Dr. Richard McIndoe, University of  Washington 
Genetics of MS: Dr. G.C. Ebers, University of Western Ontario
Potential of Viruses to Trigger MS: Dr. Kai Wucherpfennig, Dana Farber
Link between Herpes and Pathogenesis of MS: Dr. Richard Garber,
PathoGenesis

Panel on Recombinant interferon beta
Dr. John Alam, Biogen
Dr. Ayad Abdul-Ahad, Ares-Serono 

MEDIATORS
TNF Receptors for Treatment of MS: 
	Dr. David Martin, Amgen
Use of Thalidomide to Suppress Tumor Necrosis Factor in MS:  
	Dr. Lawrence W. Myers, UCLA
Matrix Metalloprotease Inhibitors for Treatment of MS: 
	Dr. Koenraad Gijbels,  Stanford

VACCINES
Developement of Altered Peptide Ligand Therapy for MS: 
	Dr. Paul Conlon, Neurocrine Biosciences
T Cell Receptor Peptide Vaccine as an Immunotherapy for MS:  
	Dr. Steven Brostoff, Immune Response
T Cell Receptor Peptide-Based Vaccine for MS: 
	Dr. Edward Amento, Connective Therapeutics 
Treatment of Multiple Sclerosis by Soluble MHC II-Peptide Complexes:

	Dr. Bishwajit Nag, Anergen, Inc. 
Treatment of Multi-component Murine EAE by One T-cell Reactive
Peptide: 
	Dr. Barbara Wallner, ImmuLogic  

IMMUNOLOGICAL THERAPY
Development of Apogens for Treatment of MS: 
	Dr. John Mueller, Alexion 
CD4-derived Peptides & Peptidomimetics as Inhibitors of MS: 
	Dr. Ziwei Huang, Jefferson Medical College 
Oral Tolerance Therapy in MS: Dr. Robert Bishop, AutoImmune
Development of T Cell Receptor Specific Monoclonal Antibody Therapy
for MS:  
	Dr. Carl 	Harald Janson, Astra Arcus (Sweden) 
Copaxone:Clinical Efficacy and Safety in Relapsing-Remitting MS
Patients:
	Dr. Ben Zion Weiner, Teva 

For more information on this meeting contact Cambridge Healthtech
Institute.  Please include your full mailing address and fax number
(if applicable).
______________________________
Cambridge Healthtech Institute      
1037 Chestnut Street
Newton Upper Falls, MA  02164
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
tel: 617.630.1300
fax: 617.630.1325
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
inquiries at healthtech.com
World Wide Web http://www.healthtech.com/conferences




More information about the Neur-sci mailing list